Contractility Study

Cardiac Contractility Service

The best choice for reliable human cardiac toxicity and efficacy testing!

Our cardiac contractility service based on the FLEXcyte 96 platform is an end-to-end safety and efficacy testing service with your drug candidate(s). We plan, prepare and conduct your contractility study for you!

The FLEXcyte 96 delivers functional measurements at physiological mechanical conditions. Acute or chronic (up to 5+ days) cardiac toxicity or efficacy assessment is possible, with comprehensive parameter measurements from human iPSC-derived cardiomyocytes, including:

  • Contraction amplitude
  • Beat rate
  • Upstroke and downstroke velocity
  • Duration and integral
  • Arrhythmic events

Not only that, but due to the mechanical environment given by the FLEXcyte 96 culture plates also maturation of cells and physiological responses to positive inotropic agents are supported.

We offer

True contractility – physiological mechanical environment enables the cells to act naturally and show mature behaviour

35 years of experience – benefit from our combined 35 years of experience in the field of cardiac contractility assays

iPSC-derived cardiomyocyte expertise – we have validated a broad range of commercially available human iPSC-derived cardiomyocytes using the Flexcyte 96 system, and would be happy to advise on these based on your goals.

Functional cell model characterization – gain deep insight into your current cell model

You get

Flexibility – Studies can easily be tailored according to your specific needs

Saved time and resources – our experts will prepare and perform the service in our state-of-the-art cell culture facilities

Reduced costs – The 96well plate system allows for higher throughput at lower cost

Detailed results and report – our experts will deliver a summary of all essential study parameters and results of your sample material

Example Data – Positive Inotropes

Please click on the plots to see more details

Interested?

"The FLEXcyte brings another dimension to iPS-derived cardiomyocyte based assays. Measuring contractility in such a direct and easy way allows us to understand the cell functionality better and will help us in both our product development and safety pharmacology research"

Choong-seong (Henry) Han,
CEO, Founder, D.D.S., Ph.D.,
NEXEL Co., Ltd.